# Bambusa Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bambusa-therapeutics

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.bambusatx.com
- Total disclosed funding: $62M
- Latest round: Series A (Feb 12, 2025)
- Investors on record: 9

## About

Based in Massachusetts, US, and founded in 2024, Bambusa Therapeutics Inc., a.k.a. Bambusa Therapeutics is a biotechnology company that focuses on developing bispecific antibodies for the treatment of immunological and inflammatory disorders. In September 2024, Bambusa Therapeutics Inc. raised USD 15 million in seed funding co-led by BVF Partners and KKR, with participation from Salvia Group GmbH and INCE Capital. As of September 2024, Shanshan Xu is the CEO of the company.

The company is developing transformative inflammatory and immunological therapeutics by leveraging validated targets to achieve disease profiles for multiple indications.

The company plans to use its proceeds from September 2024 funding to expedite the development of its pipeline of bispecific antibodies for Phase I clinical studies.

## Funding rounds

- Series A, Feb 12, 2025, $53M — KKR, Invus [DUP], Redmile Group, BVF Partners, RA Capital Management, Janus Henderson Investors, INCE Capital, ADAR1 Capital Management, Salvia Group GmbH
- Seed, Jan 8, 2025, $9M — KKR, BVF Partners, INCE Capital, Salvia Group GmbH

## Investors

- KKR (https://capitalatlas.ai/funds/kkr) — Seed, Series A
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Seed, Series A
- INCE Capital (https://capitalatlas.ai/funds/ince-capital) — Seed, Series A
- Salvia Group GmbH — Seed, Series A
- Invus [DUP] — Series A
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series A
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A
- Janus Henderson Investors — Series A
- ADAR1 Capital Management (https://capitalatlas.ai/funds/adar1-capital-management) — Series A